Prognostic factors for survival in advanced thymomas: The role of the number of involved structures

被引:10
作者
Chiappetta, Marco [1 ,2 ]
Aprile, Vittorio [3 ]
Lococo, Filippo [1 ,2 ]
Zanfrini, Edoardo [1 ,2 ]
Nachira, Dania [1 ,2 ]
Meacci, Elisa [1 ,2 ]
Korasidis, Stylianos [3 ]
Ambrogi, Marcello [3 ]
Lucchi, Marco [3 ]
Margaritora, Stefano [1 ,2 ]
机构
[1] Univ Cattolica Sacro Cuore, LARGO A Gemelli 8, I-00100 Rome, Italy
[2] Fdn Policlin Univ A Gemelli IRCCS, Dept Thorac Surg, LARGO A Gemelli 8, I-00100 Rome, Italy
[3] Univ Pisa, Dept Cardiac Thorac & Vasc, Thorac Surg, Pisa, Italy
关键词
adjuvant therapy; surgery; survival; thymoma; THYMIC EPITHELIAL TUMORS; FORTHCOMING 8TH EDITION; INTERNATIONAL ASSOCIATION; TNM CLASSIFICATION; EUROPEAN-SOCIETY; STAGING SYSTEM; RADIOTHERAPY; CARCINOMA; PROPOSAL; THERAPY;
D O I
10.1002/jso.26593
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and Objectives The Masoka-Koga and tumor node metastases staging systems for thymoma are based on structures involved, but the prognostic role of the number of infiltrated/involved structures is still debated. We analyzed the prognostic role of involved structures and their combinations in locally advanced thymomas patients. Methods Data on 174 surgically treated locally advanced thymoma patients from 1/01/1990 to 31/12/2015 were reviewed. Clinical and pathological characteristic, involved structures, number of involved structures and different combinations were correlated to cancer specific survival (CSS) using Kaplan-Meier product-limit method. Results Five and 10-year CSS was 92% and 87%. Masaoka Stage 3 (p < 0.001), absence of pericardial involvement (p = 0.001), number of involved structures (p = 0.018), R0 (p < 0.001) and adjuvant radiotherapy (p = 0.008) were favorable prognostic CSS factors. A significant better prognosis was present in <= 2 involved structures vs >2 involved structures (5- and 10-year CSS: 95% and 93% vs. 80% and 51%). Multivariable analysis confirmed as independent prognostic factor R0 (p = 0.033, hazard ratio [HR]: 0.093, 95% confidence interval [CI] 0.010-0.827) and number of involved structures (p = 0.046, HR: 0.187, 95% CI: 0.036-0.968). In Masaoka Stage 3, patients with <= 2 involved structures had a significant better CSS than patients with >2 (10-year CSS: 98% vs. 73%, p = 0.008). Conclusions The number of involved structures and the concomitant involvement of the pericardium seems to be associated with a poor prognosis in surgically treated advanced thymoma patients.
引用
收藏
页码:858 / 866
页数:9
相关论文
共 19 条
[1]   A Population-Based Study of Incidence and Survival of 1588 Thymic Malignancies: Results From the California Cancer Registry [J].
Benjamin, David J. ;
Klapheke, Amy ;
Lara, Primo N. ;
Cress, Rosemary D. ;
Riess, Jonathan W. .
CLINICAL LUNG CANCER, 2019, 20 (06) :477-483
[2]   Prognostic factors after treatment for iterative thymoma recurrences: A multicentric experience [J].
Chiappetta, Marco ;
Zanfrini, Edoardo ;
Giraldi, Luca ;
Mastromarino, Maria Giovanna ;
Petracca-Ciavarella, Leonardo ;
Nachira, Dania ;
Congedo, Maria Teresa ;
Aprile, Vittorio ;
Ambrogi, Marcello Carlo ;
Lucchi, Marco ;
Filosso, Pier Luigi ;
Ruffini, Enrico ;
Guerrera, Francesco ;
Mule, Antonino ;
Ali, Greta ;
Molinaro, Luca ;
Lococo, Filippo ;
Meacci, Elisa ;
Margaritora, Stefano .
LUNG CANCER, 2019, 138 :27-34
[3]   Thymic epithelial turnours: A population-based study of the incidence, diagnostic procedures and therapy [J].
de Jong, Wouter K. ;
Blaauwgeers, Johannes L. G. ;
Schaapveld, Michael ;
Timens, Wim ;
Klinkenberg, Theo J. ;
Groen, Harry J. M. .
EUROPEAN JOURNAL OF CANCER, 2008, 44 (01) :123-130
[4]   The IASLC/ITMIG Thymic Epithelial Tumors Staging Project: Proposal for an Evidence-Based Stage Classification System for the Forthcoming (8th) Edition of the TNM Classification of Malignant Tumors [J].
Detterbeck, Frank C. ;
Stratton, Kelly ;
Giroux, Dorothy ;
Asamura, Hisao ;
Crowley, John ;
Falkson, Conrad ;
Filosso, Pier Luigi ;
Frazier, Aletta A. ;
Giaccone, Giuseppe ;
Huang, James ;
Kim, Jhingook ;
Kondo, Kazuya ;
Lucchi, Marco ;
Marino, Mirella ;
Marom, Edith M. ;
Nicholson, Andrew G. ;
Okumura, Meinoshin ;
Ruffini, Enrico ;
Van Schil, Paul .
JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (09) :S65-S72
[5]   Management of Stage I and II Thymoma [J].
Detterbeck, Frank C. ;
Parsons, Alden M. .
THORACIC SURGERY CLINICS, 2011, 21 (01) :59-+
[6]   Clinical evaluation of a new tumour-node-metastasis staging system for thymic malignancies proposed by the International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee and the International Thymic Malignancy Interest Group [J].
Fukui, Takayuki ;
Fukumoto, Koichi ;
Okasaka, Toshiki ;
Kawaguchi, Koji ;
Nakamura, Shota ;
Hakiri, Shuhei ;
Ozeki, Naoki ;
Hirakawa, Akihiro ;
Tateyama, Hisashi ;
Yokoi, Kohei .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2016, 49 (02) :574-579
[7]   Thymic epithelial tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro [J].
Girard, N. ;
Ruffini, E. ;
Marx, A. ;
Faivre-Finn, C. ;
Peters, S. .
ANNALS OF ONCOLOGY, 2015, 26 :V40-V55
[8]  
KOGA K, 1994, PATHOL INT, V44, P359
[9]   Therapy for thymic epithelial tumors: A clinical study of 1,320 patients from Japan [J].
Kondo, K ;
Monden, Y .
ANNALS OF THORACIC SURGERY, 2003, 76 (03) :878-884
[10]   Adjuvant Radiotherapy for Thymic Epithelial Tumors: A Systematic Review and Meta-Analysis [J].
Korst, Robert J. ;
Kansler, Amanda L. ;
Christos, Paul J. ;
Mandal, Sanjay .
ANNALS OF THORACIC SURGERY, 2009, 87 (05) :1641-1647